Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) – Research analysts at Jefferies Group lifted their FY2016 earnings estimates for Progenics Pharmaceuticals in a note issued to investors on Tuesday. Jefferies Group analyst G. Wang now expects that the firm will post earnings per share of $0.03 for the year, up from their previous estimate of $0.02. Jefferies Group has a “Buy” rating and a $11.00 price target on the stock. Jefferies Group also issued estimates for Progenics Pharmaceuticals’ Q4 2016 earnings at ($0.22) EPS, FY2017 earnings at ($0.66) EPS, FY2018 earnings at ($0.42) EPS, FY2019 earnings at $0.08 EPS and FY2020 earnings at $0.37 EPS.

A number of other equities research analysts have also recently commented on PGNX. Needham & Company LLC set a $11.00 price objective on Progenics Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, December 18th. Aegis reissued a “buy” rating and issued a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Tuesday, November 8th. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 14th. TheStreet raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 7th. Finally, BTIG Research boosted their target price on Progenics Pharmaceuticals from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, November 30th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Progenics Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $10.29.

Earnings History and Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/progenics-pharmaceuticals-inc-to-post-fy2016-earnings-of-0-03-per-share-jefferies-group-forecasts-pgnx.html.

Progenics Pharmaceuticals (NASDAQ:PGNX) opened at 8.96 on Friday. Progenics Pharmaceuticals has a one year low of $3.61 and a one year high of $9.78. The firm has a market cap of $627.66 million, a price-to-earnings ratio of 57.81 and a beta of 3.11. The stock’s 50 day moving average price is $8.83 and its 200-day moving average price is $6.64.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings data on Monday, November 7th. The company reported $0.52 EPS for the quarter, missing the Zacks’ consensus estimate of $0.55 by $0.03. The company had revenue of $53.90 million for the quarter, compared to analyst estimates of $52.90 million. Progenics Pharmaceuticals had a net margin of 15.55% and a return on equity of 12.27%. The business’s revenue was up 3750.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) EPS.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP acquired a new position in Progenics Pharmaceuticals during the third quarter worth about $23,110,000. BlackRock Fund Advisors boosted its position in Progenics Pharmaceuticals by 5.1% in the third quarter. BlackRock Fund Advisors now owns 2,859,154 shares of the company’s stock worth $18,098,000 after buying an additional 139,469 shares during the last quarter. Vanguard Group Inc. boosted its position in Progenics Pharmaceuticals by 9.7% in the second quarter. Vanguard Group Inc. now owns 2,737,391 shares of the company’s stock worth $11,552,000 after buying an additional 241,227 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Progenics Pharmaceuticals by 9.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,940,553 shares of the company’s stock worth $12,284,000 after buying an additional 163,595 shares during the last quarter. Finally, Phocas Financial Corp. boosted its position in Progenics Pharmaceuticals by 145.4% in the third quarter. Phocas Financial Corp. now owns 1,593,088 shares of the company’s stock worth $10,084,000 after buying an additional 943,793 shares during the last quarter. 86.03% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at http://www.dailypolitical.com/2017/01/13/progenics-pharmaceuticals-inc-to-post-fy2016-earnings-of-0-03-per-share-jefferies-group-forecasts-pgnx.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

5 Day Chart for NASDAQ:PGNX

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.